This Phase 1 trial is being conducted in the United States / REUTERS
This Phase 1 trial is being conducted in the United States.
Pfizer Inc. announced on Tuesday that it is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for SARS-CoV-2, the virus that causes COVID-19.
This Phase 1 trial is being conducted in the United States, as reported on the company's official website.
Read alsoCOVID-19 in Ukraine: Almost 14,200 new cases reported as of March 24, daily deaths hit new high
"Tackling the COVID-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus. Given the way that SARS-CoV-2 is mutating and the continued global impact of COVID-19, it appears likely that it will be critical to have access to therapeutic options both now and beyond the pandemic," said Mikael Dolsten, MD, PhD., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer.
Pfizer is also investigating an intravenously administered investigational protease inhibitor, PF-07304814, which is currently in a Phase 1b multi-dose trial in hospitalized clinical trial participants with COVID-19.